Phase IV post-approval studies in the context of vaccines approved through accelerated procedures: Case study, CHIKUNGUNYA vaccines
Workshop held in São Paulo, Brazil on 19 & 20 March 2025

CEPI and ANVISA hosted this workshop to update global regulators on the marketing authorisation and clinical development plans in preparation for phase IV studies and future global approvals. There was robust dialogue and participation from 18 countries representing 14 NRAs. Read more